Back to search results

Emotional Awareness and Expression Therapy (EAET) for Lupus and Fibromyalgia Pain

This study is testing a type of talk therapy called Emotional Awareness and Expression Therapy (EAET) for people with lupus and fibromyalgia (widespread body pain). EAET helps people understand and express emotions linked to difficult life experiences, which might reduce pain and improve overall health. Researchers want to see if EAET is safe and effective in reducing chronic pain and other symptoms in lupus patients. You could be eligible if you are 18-65 years old, have both lupus and fibromyalgia or chronic widespread pain, and are on stable medications. The study will measure changes in your widespread pain and symptom severity to see if the therapy works. Currently, the study's status is unclear.

Study design
This interventional study plans to enroll 30 participants. Participants will be randomly assigned to either receive EAET therapy or be placed on a waiting list.
What's involved
If you receive EAET, you will attend eight weekly two-hour online group therapy sessions and complete about 30 minutes of daily homework for 8 weeks. All participants will fill out questionnaires before and after the treatment.
Compensation
Not stated in the trial record.
Follow-up
Your widespread pain will be measured a week after treatment compared to baseline (9 weeks after starting treatment).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07282392

Helping Lupus Patients Manage Fibromyalgia Symptoms Through Emotional Awareness and Expression Therapy (EAET)

Recruiting
NAAges 18–65InterventionalTreatment
University of Utah
~30 participants
Updated 2025-12-29 on ClinicalTrials.gov
What's tested:Emotional Awareness and Expression Therapy (EAET)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Widespread pain index at baseline
Measured over From enrollment to the end of treatment at 8 weeks
+3 more outcomes measured

Conditions

Lupus
Fibromyalgia (FM)
Chronic Widespread Pain

Explore related trials

FibromyalgiaLupus ErythematosusPain Amplification Syndrome

Where it's being run

1 sites across 1 states
Utah1

Study leadership

  • Dan Kaufmann, PhD · PRINCIPAL_INVESTIGATOR · University of Utah

Who to contact

Dan Kaufmann, PhD
[email protected]
385-351-9058
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults of all genders, ages 18-65.
A diagnosis of lupus and fibromyalgia or chronic widespread pain by a licensed rheumatologist
Be on a stable medication regimen.

Exclusion

Serious psychiatric disorders (e.g., schizophrenia or bipolar disorder) uncontrolled with medications.
Active suicidal ideation.
Untreated alcohol or substance use disorder.
Substantial cognitive impairment.
Changes in medications in the past 3 months.
Enrollment in another treatment study.
Current involvement in health-related litigation or disability application.
Inability to use a computer and/or smartphone.
limited access to the internet.
Inability to communicate in English.
Failure to complete the baseline assessments.

What this trial measures

  • Widespread pain index at baselineFrom enrollment to the end of treatment at 8 weeks

    A licensed rheumatologist will ask participants to identify 19 areas where they felt pain over the past week. The score ranges from 0 to 19 (the number of bodily regions).

  • Widespread pain index a week after treatment compared to baseline9 weeks after commencement of treatment

    A licensed rheumatologist will ask participants how many body areas they felt pain in during the week after treatment. The score ranges from 0 to 19, and the change in score will be compared with the baseline score. A lower score after treatment indicates the treatment's effectiveness in reducing widespread pain.

  • Symptom Severity Score at baseline1 week before the treatment

    A licensed rheumatologist will evaluate the symptom severity and somatic symptoms over the past week at baseline using a 0-3 scale.

  • Change in the severity scale after treatment compared to baseline.9 weeks after commencement of treatment

    A change in symptom severity will be evalauted by comparing the symptom severity score after treatment to baseline. A lower severity score after treatment indicates the treatment's effectiveness in reducing somatic symptoms.